<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35673968</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>18</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4598</ISSN><JournalIssue CitedMedium="Internet"><Volume>66</Volume><Issue>4</Issue><PubDate><Year>2022</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Muscle &amp; nerve</Title><ISOAbbreviation>Muscle Nerve</ISOAbbreviation></Journal><ArticleTitle>Gold Coast criteria expand clinical trial eligibility in amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>397</StartPage><EndPage>403</EndPage><MedlinePgn>397-403</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/mus.27660</ELocationID><Abstract><AbstractText Label="INTRODUCTION/AIMS">Consensus criteria to formalize the diagnosis of amyotrophic lateral sclerosis (ALS) and refine clinical trial populations have evolved. The recently proposed Gold Coast consensus criteria are intended to simplify use and increase sensitivity. We aimed to evaluate the potential impact of these criteria on clinical trial eligibility.</AbstractText><AbstractText Label="METHODS">We performed a single-center, retrospective study of people diagnosed with ALS between 2016 and 2021 to determine the numbers of those meeting Gold Coast, revised El Escorial (rEEC) criteria, and Awaji criteria. We identified the proportion of those who would have been eligible for participation in three major ALS clinical trials if Gold Coast were used in place of rEEC definite/probable criteria. (rEEC D/P).</AbstractText><AbstractText Label="RESULTS">Two hundred six people with ALS were included in our study. 48.5% met Gold Coast criteria but not rEEC D/P. Using the Gold Coast criteria would result in higher rates of clinical trial eligibility after other inclusion criteria were met: 95.2% vs 42.5% (P&#x2009;&lt;&#x2009;.001) in a phase III study of riluzole; 100% vs 31.0% (P&#xa0;=&#xa0;.002) in a phase III study of edaravone; and 95.6% vs 45.3% (P&#x2009;&lt;&#x2009;.001) in an ongoing phase III study of sodium phenylbutyrate and taurursodiol. The sensitivity of the Gold Coast criteria (96.1%; 95% confidence interval [CI],&#xa0;92.2%-98.2%) was significantly higher than that of rEEC D/P (47.6%; 95% CI, 40.6%-54.6%; for difference, &#x3c7;<sup>2</sup> &#xa0;=&#xa0;117.6; P&#x2009;&lt; .001).</AbstractText><AbstractText Label="DISCUSSION">Until robust biomarkers are available to diagnose ALS, consensus diagnostic criteria remain necessary. Gold Coast criteria would expand research and clinical trial eligibility and improve external validity of clinical trial results.</AbstractText><CopyrightInformation>&#xa9; 2022 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jewett</LastName><ForeName>Gordon</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-8268-5677</Identifier><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khayambashi</LastName><ForeName>Shahin</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-5972-5901</Identifier><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frost</LastName><ForeName>Geoffrey S</ForeName><Initials>GS</Initials><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beland</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-9574-1412</Identifier><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Angela</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-9483-975X</Identifier><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hodgkinson</LastName><ForeName>Victoria</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0001-5908-2694</Identifier><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Korngut</LastName><ForeName>Lawrence</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-1594-5923</Identifier><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chhibber</LastName><ForeName>Sameer</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>06</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Muscle Nerve</MedlineTA><NlmUniqueID>7803146</NlmUniqueID><ISSNLinking>0148-639X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>S798V6YJRP</RegistryNumber><NameOfSubstance UI="D000077553">Edaravone</NameOfSubstance></Chemical><Chemical><RegistryNumber>7LJ087RS6F</RegistryNumber><NameOfSubstance UI="D019782">Riluzole</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Muscle Nerve. 2022 Oct;66(4):377-379</RefSource><PMID Version="1">35822531</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="Y">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077553" MajorTopicYN="N">Edaravone</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004608" MajorTopicYN="Y">Eligibility Determination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019782" MajorTopicYN="N">Riluzole</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Awaji criteria</Keyword><Keyword MajorTopicYN="N">El Escorial criteria</Keyword><Keyword MajorTopicYN="N">Gold Coast criteria</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">clinical trial</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>5</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>3</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>5</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>8</Day><Hour>4</Hour><Minute>22</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35673968</ArticleId><ArticleId IdType="doi">10.1002/mus.27660</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Brooks BR. El Escorial world Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on motor neuron diseases/amyotrophic lateral sclerosis of the World Federation of Neurology Research Group on neuromuscular diseases and the El Escorial &#x201c;clinical limits of amyotrophic lateral sclerosis&#x201d; workshop contributors. J Neurol Sci. 1994;124(Suppl):96-107. doi:10.1016/0022-510x(94)90191-0</Citation></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:293-299. doi:10.1080/146608200300079536</Citation></Reference><Reference><Citation>de Carvalho M, Dengler R, Eisen A, et al. Electrodiagnostic criteria for diagnosis of ALS. Clin Neurophysiol. 2008;119:497-503. doi:10.1016/j.clinph.2007.09.143</Citation></Reference><Reference><Citation>Gawel M, Kuzma-Kozakiewicz M, Szmidt-Salkowska E, Kami&#x144;ska A. Are we really closer to improving the diagnostic sensitivity in ALS patients with Awaji criteria? Amyotroph Lateral Scler Frontotemporal Degener. 2014;15:257-261. doi:10.3109/21678421.2014.887118</Citation></Reference><Reference><Citation>Costa J, Swash M, de Carvalho M. Awaji criteria for the diagnosis of amyotrophic lateral sclerosis: a systematic review. Arch Neurol. 2012;69:1410-1416. doi:10.1001/archneurol.2012.254</Citation></Reference><Reference><Citation>Geevasinga N, Loy CT, Menon P, et al. Awaji criteria improves the diagnostic sensitivity in amyotrophic lateral sclerosis: a systematic review using individual patient data. Clin Neurophysiol. 2016;127:2684-2691. doi:10.1016/j.clinph.2016.04.005</Citation></Reference><Reference><Citation>Johnsen B, Pugdahl K, Fuglsang-Frederiksen A, et al. Diagnostic criteria for amyotrophic lateral sclerosis: a multicentre study of inter-rater variation and sensitivity. Clin Neurophysiol. 2019;130:307-314. doi:10.1016/j.clinph.2018.11.021</Citation></Reference><Reference><Citation>Vucic S, Ferguson TA, Cummings C, et al. Gold Coast diagnostic criteria: implications for ALS diagnosis and clinical trial enrollment. Muscle Nerve. 2021;64:532-537. doi:10.1002/mus.27392</Citation></Reference><Reference><Citation>Traynor BJ, Codd MB, Corr B, Forde C, Frost E, Hardiman OM. Clinical features of amyotrophic lateral sclerosis according to the El Escorial and Airlie House diagnostic criteria: a population-based study. Arch Neurol. 2000;57:1171-1176. doi:10.1001/archneur.57.8.1171</Citation></Reference><Reference><Citation>van Eijk RPA, Westeneng H-J, Nikolakopoulos S, et al. Refining eligibility criteria for amyotrophic lateral sclerosis clinical trials. Neurology. 2019;92(5):e451-e460. doi:10.1212/WNL.0000000000006855</Citation></Reference><Reference><Citation>Chi&#xf2; A, Canosa A, Gallo S, et al. ALS clinical trials: do enrolled patients accurately represent the ALS population? Neurology. 2011;77:1432-1437. doi:10.1212/WNL.0b013e318232ab9b</Citation></Reference><Reference><Citation>Rothwell PM. External validity of randomised controlled trials: &#x201c;to whom do the results of this trial apply?&#x201d;. Lancet. 2005;365:82-93. doi:10.1016/S0140-6736(04)17670-8</Citation></Reference><Reference><Citation>Shefner JM, Al-Chalabi A, Baker MR, et al. A proposal for new diagnostic criteria for ALS. Clin Neurophysiol. 2020;131:1975-1978. doi:10.1016/j.clinph.2020.04.005</Citation></Reference><Reference><Citation>Swash M. Why are upper motor neuron signs difficult to elicit in amyotrophic lateral sclerosis? J Neurol Neurosurg Psychiatry. 2012;83:659-662. doi:10.1136/jnnp-2012-302315</Citation></Reference><Reference><Citation>Swash M, Burke D, Turner MR, et al. Occasional essay: upper motor neuron syndrome in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2020;91:227-234. doi:10.1136/jnnp-2019-321938</Citation></Reference><Reference><Citation>Turner MR, Barohn RJ, Corcia P, et al. Primary lateral sclerosis: consensus diagnostic criteria. J Neurol Neurosurg Psychiatry. 2020;91:373-377. doi:10.1136/jnnp-2019-322541</Citation></Reference><Reference><Citation>Hannaford A, Pavey N, van den Bos M, et al. Diagnostic utility of Gold Coast criteria in amyotrophic lateral sclerosis. Ann Neurol. 2021;89:979-986. doi:10.1002/ana.26045</Citation></Reference><Reference><Citation>Pugdahl K, Camdessanch&#xe9; J-P, Cengiz B, et al. Gold Coast diagnostic criteria increase sensitivity in amyotrophic lateral sclerosis. Clin Neurophysiol. 2021;132:3183-3189. doi:10.1016/j.clinph.2021.08.014</Citation></Reference><Reference><Citation>Bensimon G, Lacomblez L, Meininger V. A controlled trial of Riluzole in amyotrophic lateral sclerosis. N Engl J Med. 1994;330:585-591. doi:10.1056/NEJM199403033300901</Citation></Reference><Reference><Citation>Abe K, Aoki M, Tsuji S, et al. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16:505-512. doi:10.1016/S1474-4422(17)30115-1</Citation></Reference><Reference><Citation>Amylyx Pharmaceuticals, Inc. A phase III, randomized, double-blind, placebo-controlled, multicenter trial to evaluate the safety and efficacy of AMX0035 versus placebo for 48-week treatment of adult patients with amyotrophic lateral sclerosis (ALS). 2021. https://clinicaltrials.gov/ct2/show/NCT05021536.</Citation></Reference><Reference><Citation>Bossuyt PM, Reitsma JB, Bruns DE, et al. An updated list of essential items for reporting diagnostic accuracy studies. BMJ. 2015;351:h5527. doi:10.1136/bmj.h5527</Citation></Reference><Reference><Citation>Ince PG, Evans J, Knopp M, et al. Corticospinal tract degeneration in the progressive muscular atrophy variant of ALS. Neurology. 2003;60:1252-1258. doi:10.1212/01.wnl.0000058901.75728.4e</Citation></Reference><Reference><Citation>Riku Y, Atsuta N, Yoshida M, et al. Differential motor neuron involvement in progressive muscular atrophy: a comparative study with amyotrophic lateral sclerosis. BMJ Open. 2014;4:e005213. doi:10.1136/bmjopen-2014-005213</Citation></Reference><Reference><Citation>Kim W-K, Liu X, Sandner J, et al. Study of 962 patients indicates progressive muscular atrophy is a form of ALS. Neurology. 2009;73:1686-1692. doi:10.1212/WNL.0b013e3181c1dea3</Citation></Reference><Reference><Citation>Alanazy MH, White C, Korngut L. Diagnostic yield and cost-effectiveness of investigations in patients presenting with isolated lower motor neuron signs. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15:414-419. doi:10.3109/21678421.2014.913635</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>